Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC cut its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 36.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,250,000 shares of the company's stock after selling 1,291,505 shares during the period. Avoro Capital Advisors LLC owned about 2.89% of Kura Oncology worth $19,598,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after acquiring an additional 615,211 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock worth $34,798,000 after purchasing an additional 41,535 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock worth $28,687,000 after purchasing an additional 23,113 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Kura Oncology by 35.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,425,960 shares of the company's stock valued at $12,419,000 after purchasing an additional 372,196 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Kura Oncology during the 4th quarter valued at $8,265,000.

Kura Oncology Stock Performance

NASDAQ:KURA remained flat at $6.43 during mid-day trading on Friday. 984,566 shares of the company traded hands, compared to its average volume of 1,147,182. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm's fifty day simple moving average is $6.88 and its 200-day simple moving average is $10.05. The company has a market capitalization of $519.40 million, a P/E ratio of -2.72 and a beta of 0.83. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $23.48.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analysts' expectations of $57.96 million. Sell-side analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock worth $92,307 over the last ninety days. 6.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KURA. BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. UBS Group reduced their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. StockNews.com raised shares of Kura Oncology from a "hold" rating to a "buy" rating in a research note on Friday, April 4th. Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Kura Oncology currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.50.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.